The FDA has granted a fast track designation to BI 764532 for the treatment of patients with extensive-stage small cell lung cancer that has progressed following at least 2 prior lines of treatment, and for patients with advanced or metastatic extrapulmonary neuroendocrine carcinoma that has progressed following at least 1 prior line of treatment.
Martin Wermke, MD, discusses why the novel T-cell engager BI 764532 may serve as a promising treatment option targeting DLL3 in small cell lung cancer and neuroendocrine carcinomas .